Novo Nordisk (NVO) today announced a $73 million expansion of its Clayton, NC manufacturing facility to accommodate increased production capacity for the company’s insulin delivery devices.
The company said in statement that its initial expansion will create 205 new jobs, including 85 in the Novo Nordisk Clayton facility.
Novo Nordisk currently has more than 420 employees in Clayton who oversee the full production process for six different diabetes treatment products. The expansion will include the addition of two final assembly lines, two packing lines and building refurbishment.
“The investment to expand our Clayton facility is another example of our commitment to improving diabetes treatment options in the U.S. by ensuring patients have access to the latest advances in treatment,” said in a statement Jerzy Gruhn, president of Novo Nordisk Inc.
NVO shares fell $1.97, or 1.98%, to $97.30 in Monday trading.
Bagsvaerd, Denmark -based Novo Nordisk is a healthcare company that engages in the manufacturing and marketing of pharmaceutical products. It operates in two segments, Diabetes Care and Biopharmaceuticals.